D. M. Parkin, F. Bray, J. Ferlay, and P. Pisani, Global Cancer Statistics, 2002, CA: A Cancer Journal for Clinicians, vol.55, issue.2, pp.74-108, 2002.
DOI : 10.3322/canjclin.55.2.74

M. Pirisi, C. Avellini, and C. Fabris, Portal vein thrombosis in hepatocellular carcinoma: age and sex distribution in an autopsy study, Journal of Cancer Research and Clinical Oncology, vol.124, issue.7, pp.397-400, 1998.
DOI : 10.1007/s004320050189

P. Tandon and G. Garcia-tsao, Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies, Liver International, vol.101, issue.(S, pp.502-510, 2009.
DOI : 10.1111/j.1478-3231.2008.01957.x

J. M. Llovet, C. Brú, and J. Bruix, Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification, Seminars in Liver Disease, vol.19, issue.03, pp.329-338, 1999.
DOI : 10.1055/s-2007-1007122

F. Perrone, Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. he Cancer of the Liver Italian Program (CLIP) Investigators, Hepatology, vol.31, issue.4, pp.840-845, 2000.

J. L. Raoul, B. Sangro, and A. Forner, Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: Available evidence and expert opinion on the use of transarterial chemoembolization, Cancer Treatment Reviews, vol.37, issue.3, pp.212-220, 2011.
DOI : 10.1016/j.ctrv.2010.07.006
URL : https://hal.archives-ouvertes.fr/hal-01134844

Z. S-u-n, G. L-i, and X. , H e p a t i ca n db i l i a r yd a m a g ea t e r transarterial chemoembolization for malignant hepatic tumors: incidence, diagnosis, treatment, outcome and mechanism, Critical Reviews in OncologyHematology, vol.79, issue.2, pp.164-174, 2011.

J. M. Llovet, J. Bustamante, and A. Castellsetal, Natural history of untreated nonsurgical hepatocellular carcinoma: Rationale for the design and evaluation of therapeutic trials, Hepatology, vol.16, issue.1, pp.62-67, 1999.
DOI : 10.1002/hep.510290145

J. M. Llovet, S. Ricci, and V. Mazzaferro, Sorafenib in Advanced Hepatocellular Carcinoma, New England Journal of Medicine, vol.359, issue.4, pp.378-390, 2008.
DOI : 10.1056/NEJMoa0708857

P. Sorrentino, L. , S. J. D-'angeloetal, D. Raoul, J. F. Guyader et al., Validation of an extension of the international non-invasive criteria for the diagnosis of hepatocellular carcinoma to the characterization of macroscopic portal vein thrombosis, Journal of Gastroenterology and Hepatology, vol.254, issue.1, pp.669-677, 1994.
DOI : 10.1111/j.1440-1746.2010.06564.x

P. Hilgard, M. Hamami, and A. E. Fouly, Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival, Hepatology, vol.74, issue.5, pp.1741-1749, 2010.
DOI : 10.1002/hep.23944

M. Iñarrairaegui, K. G. Hurston, and J. I. Bilbaoetal, Radioembolization with Use of Yttrium-90 Resin Microspheres in Patients with Hepatocellular Carcinoma and Portal Vein Thrombosis, Journal of Vascular and Interventional Radiology, vol.21, issue.8, pp.1205-1212, 2010.
DOI : 10.1016/j.jvir.2010.04.012

L. M. Kulik, B. I. Carr, and M. F. Mulcahy, Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis, Hepatology, vol.42, issue.Suppl 1, pp.71-81, 2008.
DOI : 10.1002/hep.21980

R. Salem, R. Lewandowski, and C. Roberts, Use of Yttrium-90 Glass Microspheres (TheraSphere) for the Treatment of Unresectable Hepatocellular Carcinoma in Patients with Portal Vein Thrombosis, Journal of Vascular and Interventional Radiology, vol.15, issue.4, pp.335-345, 2004.
DOI : 10.1097/01.RVI.0000123319.20705.92

R. Salem, R. J. Lewandowski, and M. F. Mulcahy, Radioembolization for Hepatocellular Carcinoma Using Yttrium-90 Microspheres: A Comprehensive Report of Long-term Outcomes, Gastroenterology, vol.138, issue.1, pp.52-64, 2010.
DOI : 10.1053/j.gastro.2009.09.006

A. L. Sai, C. T. Burke, and A. S. Kennedyetal, Use of Yttrium-90 Microspheres in Patients with Advanced Hepatocellular Carcinoma and Portal Vein Thrombosis, Journal of Vascular and Interventional Radiology, vol.21, issue.9, pp.1377-1384, 2010.
DOI : 10.1016/j.jvir.2010.04.027

C. E. Woodall, C. R. Scoggins, and S. F. Ellis, Is selective internal radioembolization safe and efective for patients with inoperable hepatocellular carcinoma and venous thrombosis, JournaloftheAmericanCollegeofSurgeons, vol.208, issue.3, pp.375-382, 2009.

J. Bruix, M. Sherman, and J. M. Llovet, Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference, Journal of Hepatology, vol.35, issue.3, pp.421-430, 2001.
DOI : 10.1016/S0168-8278(01)00130-1

M. E. Hamami, T. D. Poeppel, and S. Müller, SPECT/CT with99mTc-MAA in radioembolization with90Y microspheres in patients with hepatocellular cancer, JournalofNuclearMedicine, vol.50, issue.5, pp.688-692, 2009.

R. Salem and K. G. Hurston, Radioembolization with 90Yttrium Microspheres: A State-of-the-Art Brachytherapy Treatment for Primary and Secondary Liver Malignancies, Journal of Vascular and Interventional Radiology, vol.17, issue.9, pp.1425-1439, 2006.
DOI : 10.1097/01.RVI.0000235779.88652.53

S. , W. Y. , and T. W. L-e-u-n-ge-ta-l, P a r t i t i o nm o d e lf o r estimating radiation doses from yttrium-90 microspheres in treating hepatic tumours, pp.947-952, 1996.

A. Trotti, A. D. Colevas, and A. Setseretal, CTCAEv3.0:develop- ment of a comprehensive grading system for the adverse efects of cancer treatment, Seminars in Radiation Oncology, vol.3, issue.13, pp.176-181, 2003.

B. Gr-o and L. , Ca rpa n e se ,R.C i a n n ie tal . , " S u rv i v ala t e ry t t ri - um?90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation, Hepatology, vol.54, issue.3, pp.868-878, 2011.

V. Mazzaferro, C. Sposito, and S. Bhoori, Yttrium(90) radioembolization for intermediate-advanced hepatocarcinoma: a phase II study, Hepatology.InPress

J. Bruix, A. Cheng, and Y. , Efectofmacroscopicvascular invasion (MVI), extrahepatic spread (EHS), and ECOG performance status (ECOG PS) on outcome in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib: analysis of two phase III, randomized, double-blind trials, Journal of Clinical Oncology, vol.15, 2011.

J. L. Raoul, E. Boucher, Y. Rolland, and E. Garin, Treatment of hepatocellular carcinoma with intra-arterial injection of radionuclides, Nature Reviews Gastroenterology & Hepatology, vol.49, issue.1, pp.4-5
DOI : 10.1038/nrgastro.2009.202
URL : https://hal.archives-ouvertes.fr/hal-00742471

R. Salem, R. J. Lewandowski, and L. Kulik, Radioembolization Results in Longer Time-to-Progression and Reduced Toxicity Compared With Chemoembolization in Patients With Hepatocellular Carcinoma, Gastroenterology, vol.140, issue.2, pp.497-507, 2011.
DOI : 10.1053/j.gastro.2010.10.049

S. M. Ibrahim, R. J. Lewandowski, and K. T. Sato, Radioembolization for the treatment of unresectable hepatocellular carcinoma: A clinical review, World Journal of Gastroenterology, vol.14, issue.11, pp.1664-1669, 2008.
DOI : 10.3748/wjg.14.1664

R. Lencioni and J. M. Llovet, Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma, Seminars in Liver Disease, vol.30, issue.01, pp.52-60, 2010.
DOI : 10.1055/s-0030-1247132

E. Garin, L. Lenoir, and Y. Rolland, Dosimetry Based on 99mTc-Macroaggregated Albumin SPECT/CT Accurately Predicts Tumor Response and Survival in Hepatocellular Carcinoma Patients Treated with 90Y-Loaded Glass Microspheres: Preliminary Results, Journal of Nuclear Medicine, vol.53, issue.2, pp.255-263, 2012.
DOI : 10.2967/jnumed.111.094235
URL : https://hal.archives-ouvertes.fr/hal-00866987

C. Chiesa, M. Maccauro, and R. Romitoetal, Need,feasibilityand convenience of dosimetric treatment planning in liver selective internal radiation therapy with (90)Y microspheres: the experience of the National Cancer Institute of Milan, Quarterly Journal of Nuclear Medicine and Molecular Imaging, vol.55, issue.2, pp.168-197, 2011.

R. D. Timmerman, C. S. Bizekis, and H. I. Pass, Local Surgical, Ablative, and Radiation Treatment of Metastases, CA: A Cancer Journal for Clinicians, vol.59, issue.3, pp.145-170, 2009.
DOI : 10.3322/caac.20013